MyoKardia Presents 36-week Data from PIONEER-OLE Study of Mavacamten at the European Society of Cardiology Congress 2019 Durability of Mavacamten's Safety and Efficacy Profile Demonstrated through Nine Months in this Study of Patients with Symptomatic, Obstructive HCM Statistically Significant Changes in Key Biomarkers...

MyoKardia Announces Positive Six-Month Safety and Efficacy Data from PIONEER-OLE Study of Mavacamten for the Treatment of Symptomatic, Obstructive HCM Mavacamten Well Tolerated; Results Show Statistically Significant Elimination of Obstruction and Durable NYHA Class Improvements Statistically Significant Improvement in Several Key Biomarkers...